Study summary
A bispecific antibody cleared visible disease in about 3 in 4 people with relapsed mantle cell lymphoma
78.3%complete response rate
What was tested
Glofitamab, a bispecific antibody that links T cells to lymphoma cells, given for a fixed period, for relapsed or refractory mantle cell lymphoma, most after a BTK inhibitor.
What they found
- Complete response rate was 78.3% and overall response rate 85.0%.
- People had received a median of two earlier treatments.
What it means
Led to the GLOBRYTE phase 3 trial against standard choices after BTK inhibitors.
Last reviewed 2026-11-15 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.